SENORES1,468.00

Senores Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSANOFIINNOVACAPMOREPENLABIOLCPFDCPGHLSANOFICONRORCHPHARMAMcap ₹6,760 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)225.56285.21285.21
Receivable Days (DSO)113.54187.41187.41
Payable Days (DPO)267.74749.74606.53
Cash Conversion Cycle (days)71.36-277.12-133.91
Working Capital Turnover0.831.631.78
Asset Turnover0.320.390.39
Cash Conversion (CFO/Net Income)-0.790.510.51
CFO/EBITDA-0.510.370.37
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.